Regulatory News:

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “the Company”), announces the publication date for its 2024 half year results and Q3, 2024 business activity:

Publication

Date

  • 2024 H1 results
  • Q3, 2024 business activity

Oct 24, 2024*

*Distribution after the close of trading

About Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

Median Technologies Emmanuelle Leygues Head of Corporate Marketing & Financial Communications +33 6 10 93 58 88 emmanuelle.leygues@mediantechnologies.com

Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59 median@alizerp.com

Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49 24 ghislaine.gasparetto@seitosei-actifin.com

Median Technologies (EU:ALMDT)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Median Technologies
Median Technologies (EU:ALMDT)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Median Technologies